VOR NASDAQ
Vor Biopharma Inc.
1W: +2.7%
1M: +6.7%
3M: -0.1%
YTD: +67.9%
1Y: -28.1%
3Y: -56.8%
5Y: -93.9%
$19.54
+1.21 (+6.60%)
Pre-Market: $19.11 (-0.43, -2.23%)
Weekly Expected Move ±7.3%
$16
$17
$18
$20
$21
Credit Risk of going bust: lower than 52% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Vor Biopharma Inc. would be worth roughly what it owes.
Total debt $2.9M against a stock market value of $1.06B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.4M (short-term plus half of long-term), stock volatility 112.3%; Altman Z'' 5.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Vor Biopharma Inc. would be worth roughly what it owes.
Total debt $2.9M against a stock market value of $1.06B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.4M (short-term plus half of long-term), stock volatility 112.3%; Altman Z'' 5.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-12-07
Earliest Filing
2025-06-26
Latest Filing
partner: 4
investor: 2
Counterparties (Filed by VOR)
6 relationshipsCompanies named in VOR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| RemeGen Co., Ltd. | — | partner | Licensee of telitacicept rights in Greater China and licensor of rights outside Greater China | 2025-06-26 | View |
| Yantai Rongpu Investment Partnership (Limited Partnership) | — | investor | Investor in the Private Placement receiving Pre-Funded Warrants | 2025-06-26 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Sales agent for At-the-Market Equity Offering | 2022-12-23 | View |
| Evercore Group L.L.C. | EVR | partner | Underwriter for the common stock offering and placement agent for the private placement. | 2022-12-07 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Underwriter for the common stock offering and placement agent for the private placement. | 2022-12-07 | View |
| RA Capital Healthcare Fund, L.P. | — | investor | Investor in the private placement of common stock. | 2022-12-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-07 | Officer/Director Change; Exhibits | View | |
| 2026-06-12 | Shareholder Vote; Exhibits | View | |
| 2026-06-08 | Regulation FD; Exhibits | View | |
| 2026-03-27 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2025-12-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-17 | Material Modification to Rights of Security Holders; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-27 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-08-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-22 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-07-10 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-06-26 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-05-23 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-20 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR